FDA approves antibody drug to protect infants against RSV
The drug Nirsevimab – which is not a vaccine – will be sold under the name Beyfortus.
Federal regulators on Monday approved a shot to protect infants and toddlers against Respiratory Syncytial Virus (RSV), the leading cause of hospitalizations among young children in the U.S. The FDA’s newly-approved treatment could mitigate hospitalizations by 80%.
Reset checks in with two experts on when the antibody drug could be available at your pediatrician’s office.
GUESTS: Dr. Allison Bartlett, associate medical director of the Pediatric Infection Control program, UChicago Medicine Comer Children’s Hospital
Dr. Anat Brinkman, assistant professor of pediatrics in Emergency Medicine, Northwestern’s Feinberg School of Medicine at Lurie Children’s Hospital
More From
Reset with Sasha-Ann Simons
FDA approves antibody drug to protect infants against RSV
The drug Nirsevimab – which is not a vaccine – will be sold under the name Beyfortus.
Federal regulators on Monday approved a shot to protect infants and toddlers against Respiratory Syncytial Virus (RSV), the leading cause of hospitalizations among young children in the U.S. The FDA’s newly-approved treatment could mitigate hospitalizations by 80%.
Reset checks in with two experts on when the antibody drug could be available at your pediatrician’s office.
GUESTS: Dr. Allison Bartlett, associate medical director of the Pediatric Infection Control program, UChicago Medicine Comer Children’s Hospital
Dr. Anat Brinkman, assistant professor of pediatrics in Emergency Medicine, Northwestern’s Feinberg School of Medicine at Lurie Children’s Hospital